• 생물정신의학
• /
• 제2권1호
• /
• pp.100-106
• /
• 1995

직접적인 근거를 제시하기는 힘드나 정신장애에서 자가면역적 요소가 병인적으로 중요하다는 단편적인 보고들이 있다. 특히 바이러스 감염은 정신장애를 유발하거나 나중에 정신장애에 대한 소지를 증가시킬 가능성이 높다. 저자들은 최근에 많은 관심을 끌고 있는 C형 간염 항체(이하 anti-HCV)의 양성율이 자가면역적 관점 및 수혈 외에도 성행위 또는 약물의 존자에서 많다는 전파경로상의 특정 때문에 정신과 환자에서 일반 인구군보다 높을 것으로 추정되어 이를 확인해 보고자 본 연구를 시행하였다. 1992년 12월 초부터 1994년 5월 말까지 정신과에 입원한 환자 중에서 무작위로 효소면역측정법 (Abbott HCV EIA kit) 에 의해서 혈청내 anti-HCV를 검사하였으며, anti-HCV 양성 환자와 anti-HCV 음성인 환자를 구분하여 여러 변인별로 비교 분석하였다. 정신과 입원환자 113명중 12명(10.6%) 에서 anti-HCV 양성이었다. anti-HCV 양성자중 간기능검사상 이상이 있는 경우가 50.0% 로서 이중 83.0%는 주정 의존자였으며, 간기능검사상 정상인 환자의 83.3%는 비주정의존자였다. 정신과 진단별 anti-HCV 양성율은 주정의존 환자의 22.2%, 정신증 환자의 2.3% (주로 양극성장애), 신경증(불안장애, 적응장애)환자의 22.2%에서 anti-HCV 양성이 나타났다. 연령, 출생계절, 임파구(%), 간기능 등 변인에 대한 유의한 상관성은 관찰되지 않았다. 결론적으로 정신과 입원환자는 정상 대조군 (3.0%)에 비해 최소한 3.5배 이상 anti-HCV 양성율이 높으므로 (P<0.05), 이에 대한 주의를 환기시킬 필요가 있다.

• Journal of Preventive Medicine and Public Health
• /
• 제25권2호
• /
• pp.172-179
• /
• 1992

The author investigated the zinc concentrations in sera of 110 methamphetaimine abusers (male 87, female 23) and of 41 healthy official workers(male 29, female 12) using inductively coupled plasma emission spectrometer. The serum zinc concentrations were analysed according to hepatitis C virus antibody(Anti HCV), hepatitis B surface antigen(HBsAg) and alanine aminotransferase(ALT) value in both groups. The analytical results were obtained as follows 1. The mean zinc concentration of MAP abuser group($298.5{\pm]246.9{\mu}g/100ml$) was 2.5 times higher than that of control group($118.8{\pm}25.4{\mu}g/100ml$). 2. The distributions of zinc concentration in both groups were skewed pattern. 3. The zinc concentrations were higher in Anti HCV-positive group and abnormal ALT value group than Anti HCV-negative group and normal ALT value group. But HBs-Ag positive group had lower zinc concentration than HBs-Ag negative group. 4. The number of anti HCV-positive subjects was increased and the zinc concentrations were decreasd in proportion to the abusing duration of MAP.

• Bulletin of the Korean Chemical Society
• /
• 제33권8호
• /
• pp.2803-2805
• /
• 2012

• 병원약사회지
• /
• 제35권4호
• /
• pp.453-462
• /
• 2018

Background : The prevalence of chronic hepatitis C virus (HCV) tends to be higher in the elderly. Pegylated interferon and ribavirin therapy (Peg-IFN/RBV) was recommended as the first-line treatment in the past decades, but this regimen showed unsatisfactory results in terms of safety and efficacy especially in elderly patients. Recently, it was demonstrated that dual therapy with daclatasvir and asunaprevir was well tolerated and led to high sustained virological response (SVR) rates, irrespective of age. We conducted a study to evaluate the efficacy and safety of daclatasvir plus asunaprevir by involving elderly patients aged above 65 years. Methods : We retrospectively analyzed clinical data from chronic hepatitis C virus (HCV) genotype 1b patients treated with daclatasvir plus asunaprevir from September 2015 to December 2016 at Seoul St. Mary's hospital. The patients were divided into two groups as elderly patients (older than 65 years) and non-elderly patients (younger than 65 years) and compared the efficacy and safety. Results : A total of 112 patients were treated with daclatasvir plus asunaprevir for chronic hepatitis C. Among them, 101 patients completed the whole treatment, and in 88 patients the amount of HCV RNA was measured after 12 weeks of treatment. There was no significant difference in SVR at 12 weeks between both the groups (p=0.68). Typically, 91.4%(32/35) of elderly patients and 94.3%(50/53) of non-elderly patients achieved SVR12. Common adverse events included elevation in transaminase level, headache, and gastrointestinal disorders. There was no statistical difference in the symptoms between the two groups. Conclusions : The combination therapy with daclatasvir plus asunaprevir exhibited similar rates of SVR12 in HCV elderly patients without leading to further adverse events compared to non-elderly patients. Therefore, it is proposed that daclatasvir plus asunaprevir therapy could be considered as an effective and safe treatment, even in patients aged over 65 years.

• 한국자기공명학회논문지
• /
• 제21권3호
• /
• pp.109-113
• /
• 2017

The hepatitis C virus (HCV) internal ribosome entry site (IRES) is an RNA structure located in the 5'-UTR of the HCV RNA genome. The HCV IRES consists of four domains I, II, III, and IV, where domains II - IV are recognized by 40S ribosomal subunit and the domain III is bound to eukaryotic initiation factor 3 (eIF3) for translation initiation. Here, we have characterized the tertiary interaction between an L-/K- rich peptide and the HCV IRES domain IV. To probe the peptide binding interface in RNA, we synthesized $^{13}C$- and $^{15}N$-double labeled RNA and the binding site was identified by using the chemical shift perturbation (CSP) NMR methods. Our results showed that the peptide binds to the upper stem of the IRES domain IV, indicating that the tertiary interaction between the IRES domain IV and the peptide would disrupt the initiation of translation of HCV mRNA by blocking the start codon exposure. This study will provide an insight into the new peptide-based anti-viral drug design targeting HCV IRES RNA.

• Archives of Pharmacal Research
• /
• 제19권6호
• /
• pp.486-489
• /
• 1996

A simple, rapid, specific and sensitive method for the detection of serum hepatitis C virus (HCV) RNA using the reverse transcription-polymerase chain reaction (RT-PCR) technique without conventional RNA extraction was developed. HCV template RNA from serum was obtained by boiling the serum at $95^{\circ}C$ for 2 min, cooling rapidly in ice and removing the proteins by cetrifugation. RT-PCR amplifications including the reverse transcription and first PCR amplification were performed in one vessel containing both of reverse transcriptase and Taq DNA polymerase. The detection of HCV RNA from $10^{-3}{\mu}l$. serum was possible with this method. The suitability of this method for clinical analysis was evaluated by assaying HCV RNA in 225 patient samples including anti-HCV antibody negatives (13 samples) and positives (212 samples) by enzyme-linked immunosorbent assay test (ELISA). Detections of HCV RNA with this method were in 4 of 13 anti-HCV antibody negative samples (30.8%) and 95 of 212 positive samples (44.8%). The present method can be completed in 1 hr and has a wide range of application for the clinical utilities to determine the viral RNAS.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권23호
• /
• pp.10209-10215
• /
• 2015

To assess the contribution of tumor necrosis factor $(TNF){\beta}$ +252 polymorphisms to risk and prognosis of hepatocellular carcinoma (HCC), we enrolled 150 pairs of sex- and age-matched patients with HCC, patients with cirrhosis alone, and unrelated healthy controls. $TNF{\beta}$ +252 genotypes were determined by polymerase chain reaction with restriction fragment length polymorphism. Multivariate analysis indicated that $TNF{\beta}$ G/G genotype [odds ratio (OR), 3.64; 95%CI, 1.49-8.91], hepatitis B surface antigen (OR, 16.38; 95%CI, 8.30-32.33), and antibodies to hepatitis C virus (HCV) (OR, 39.11; 95%CI, 14.83-103.14) were independent risk factors for HCC. There was an additive interaction between $TNF{\beta}$ G/G genotype and chronic hepatitis B virus (HBV)/HCV infection (synergy index=1.15). Multivariate analysis indicated that factors associated with $TNF{\beta}$ G/G genotype included cirrhosis with Child-Pugh C (OR, 4.06; 95%CI, 1.34-12.29), thrombocytopenia (OR, 6.55; 95%CI, 1.46-29.43), and higher serum ${\alpha}$-fetoprotein concentration (OR, 2.53; 95%CI, 1.14-5.62). Patients with $TNF{\beta}$ G/G genotype had poor cumulative survival (p=0.005). Cox proportional hazard model indicated that $TNF{\beta}$ G/G genotype was a biomarker for poor HCC survival (hazard ratio, 1.70; 95%CI, 1.07-2.69). In conclusion, there are independent and additive effects between $TNF{\beta}$ G/G genotype and chronic HBV/HCV infection on risk for HCC. It is a biomarker for poor HCC survival. Carriage of this genotype correlates with disease severity and advanced hepatic fibrosis, which may contribute to a higher risk and poor survival of HCC. Chronic HBV/HCV infected subjects with this genotype should receive more intensive surveillance for early detection of HCC.

• Bulletin of the Korean Chemical Society
• /
• 제32권4호
• /
• pp.1146-1152
• /
• 2011

The discovery of 2'-spirocyclopropyl-ribocytidine (J. Med. Chem. 2010, 53, 8150-8160) as a potent inhibitor of RNA synthesis by NS5B ($IC_{50}=7.3{\mu}M$), the RNA polymerase encoded by hepatitis C Virus (HCV), has led to the synthesis and biological evaluation of several carbocyclic versions of 2'-spiropropyl-nucleosides. The cyclopentenol intermediate 7 was successfully constructed via ring-closing metathesis (RCM) from divinyl 6. Spirocyclopropanation of enone 8 was effected by using (2-chloroethyl)-dimethylsulfonium iodide and potassium tert-butoxide to form the desired intermediate 9. The synthesized nucleoside analogues 21-24 were assayed for their ability to inhibit HCV RNA replication in a subgenomic replicon Huh7 cell line. Among them, the cytosine nucleoside analogue 22 exhibited significant anti-HCV activity ($EC_{50}= 8.2{\mu}M$).

• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2003년도 생물공학의 동향(XIII)
• /
• pp.699-700
• /
• 2003

• 한국생명과학회:학술대회논문집
• /
• 한국생명과학회 2008년도 제49회 학술심포지움 및 국제학술대회
• /
• pp.19-19
• /
• 2008